

A COMPREHENSIVE REVIEW OF TREATMENT STRATEGIES FOR HPV MANAGEMENT USING PEG AND PYRAZOMYCIN

Niranjan Babu Mudduluru^{*1}, Venkat Rao Pasupuleti², Supraja Challa Devi³

¹Department of Pharmacognosy, Seven Hills College of Pharmacy, Tirupati, A.P., India

²Department of Pharmacology, Seven Hills College of Pharmacy, Tirupati, A.P., India

³Department of Pharmacology, Seven Hills College of Pharmacy, Tirupati, A.P., India

Corresponding Author

Dr. M. Niranjan Babu

Professor, Department of Pharmacognosy Seven Hills College of Pharmacy, Tirupati, A.P.,
India – 517561, Contact: 7702484513, Email: principal.cq@jntua.ac.in

Abstract:

Human papillomavirus (HPV) continues to pose a significant global public health challenge, linked to various health risks such as cervical cancer and other malignancies. This comprehensive review explores diverse facets of HPV, including its types, transmission, associated risk factors, causes, and treatment strategies. The objectives encompass a detailed examination of HPV's etiology, current treatment modalities, market trends, and broader public health implications. The review critically evaluates the efficacy and safety profiles of existing HPV treatments, emphasizing the adverse drug reactions (ADRs) associated with each approach. Moreover, the review proposes an innovative treatment strategy involving a combination of polyethylene glycol (PEG) and pyrazomycin as a potential alternative to conventional therapies. This approach is grounded in the structural similarities between pyrazomycin and ribavirin, suggesting potential efficacy in HPV treatment. Drawing on supportive evidence from the literature, the review underscores pyrazomycin's antiviral properties and its compatibility with PEG, highlighting the need for further research into this promising treatment avenue. In conclusion, the review advocates for informed decision-making in healthcare practices and public health policy, presenting new avenues for improving HPV care through exploration of alternative treatment strategies.

Key Words: Pyrazomycin, Human papillomavirus, Polyethylene glycol,

Introduction:

Human Papillomavirus (HPV) represents a significant public health concern due to its wide prevalence and its association with various health risks, notably cervical cancer and other malignancies. With over 100 distinct types, some classified as high-risk, HPV infections impose a substantial global burden. Understanding the implications of HPV is crucial for public health efforts, as it impacts not only individuals but also broader societal health[1].

HPV is a small, non-enveloped DNA virus that infects skin or mucosal cells. Its circular, double-stranded viral genome spans approximately 8 kb and encodes 6 early proteins responsible for virus replication, along with 2 late proteins, L1 and L2, which serve as viral structural proteins. Of the more than 100 known HPV genotypes, at least 13 can cause

cancers such as cervical, anal, and oropharyngeal cancers. The most prevalent "high-risk" genotypes, HPV 16 and 18, are responsible for about 70% of all cervical cancer cases globally. In 2002, HPV was estimated to have caused nearly half a million cases and 250,000 deaths from cervical cancer, with approximately 80% occurring in developing countries. Conversely, "low-risk" genotypes like HPV 6 and 11 cause genital warts, a benign condition that affects the external genitalia but can lead to significant morbidity[2].

HPV is highly transmissible, typically peaking soon after the onset of sexual activity, and most individuals acquire the infection at some point in their lives. It encompasses a group of related viruses, some sexually transmitted, capable of infecting various body parts such as the genital area, mouth, and throat. Globally, it is the most common sexually transmitted infection (STI). While HPV infections are often transient, persistent infections, particularly with high-risk types, can precipitate the development of cancers, underscoring the critical need for effective prevention and treatment strategies[3].

	LOW RISK	HIGH RISK
HPV TYPES	1,6,10,11,32,42,44	16,18,31,33,35,39,45,51,52,56,58,59,66,68
Associated Disease	Anogenital warts Cutaneous warts Recurrent respiratory Papillomatosis	Intraepithelial neoplasia Invasive carcinoma HNSCC, Cervical cancer, Anogenital cancer, Non-melanoma skin cancer

Types of HPV: HPV is categorized into low-risk and high-risk types based on their association with cancer. Low-risk types can cause warts, while high-risk types are linked to the development of cancer. Key high-risk types include HPV 16 and 18, which are responsible for a significant proportion of cervical cancers [4].

Global Prevalence: HPV exhibits a high prevalence worldwide. According to global health organizations, the majority of sexually active individuals will acquire at least one type of HPV infection during their lifetime. The prevalence varies across regions and age groups, with higher rates observed among younger populations [5].

Context: Understanding the diverse types of HPV and its global prevalence is crucial for grasping its profound impact on public health. The subsequent sections will explore the modes of transmission, risk factors, causes, and treatment options for HPV, providing a comprehensive perspective to guide healthcare practices and public health interventions [6].

Transmission of HPV:

1. Sexual Contact: HPV is primarily transmitted through intimate skin-to-skin contact, commonly during vaginal, anal, or oral sex. Transmission can occur even without visible symptoms.

2. Vertical Transmission: Although relatively rare, HPV can be passed from an infected mother to her newborn during childbirth[7].
3. Non-Sexual Transmission: Less frequently, HPV can spread through close personal contact, such as sharing towels or touching contaminated surfaces.

Risk Factors Associated with HPV Infection:

1. Sexual Activity: Increased risk of HPV exposure is associated with early sexual activity or having multiple sexual partners.
2. Immune System Health: Individuals with weakened immune systems, due to medical conditions or immunosuppressive medications, are more susceptible to HPV infections.
3. Smoking: Tobacco use, particularly smoking, is linked to a higher likelihood of persistent HPV infections and progression to cervical cancer.
4. Genital Warts: History of genital warts or other sexually transmitted infections (STIs) can elevate the risk of acquiring or transmitting HPV.
5. Gender and Age: Adolescents and young adults are more vulnerable to HPV infections, with females generally facing a higher risk of HPV-related complications.

Understanding these modes of transmission, risk factors, and causes is essential for developing effective prevention strategies and targeted interventions aimed at reducing the incidence of HPV infections [8].

Causes of HPV: Viral Factors:

1. HPV Genotypes: HPV exists in various genotypes classified as low-risk and high-risk types. High-risk types, such as HPV 16 and 18, pose a greater risk of causing cancer.

Host-Related Factors:

1. Sexual Behavior: Initiating sexual activity at a young age and having multiple sexual partners elevate the likelihood of HPV exposure.
2. Immune System: An impaired immune system, caused by immunosuppressive medications, conditions like HIV, or other factors, can impede the body's ability to eliminate the virus.
3. Genetic Predisposition: Certain individuals may have genetic predispositions that increase their vulnerability to persistent HPV infections and the subsequent development of associated cancers [9].



Understanding How HPV Infections Occur:

1. Transmission: HPV primarily spreads through direct skin-to-skin contact, typically during sexual activity. The virus can infect genital, anal, and oral areas.

2. Microabrasions: Even minor cuts or abrasions on the skin can serve as entry points for HPV. Mucous membranes in the genital, anal, and oral regions are especially susceptible.
3. Asymptomatic Transmission: HPV infections can occur without noticeable symptoms, allowing individuals to unknowingly transmit the virus.

The interplay between viral factors and host-related factors sheds light on the complexity of HPV infections. Persistent high-risk HPV infections, combined with specific host vulnerabilities, contribute to the development of HPV-related cancers. This understanding is crucial for developing targeted prevention strategies and effective management approaches[10].

Additional Factors Influencing HPV Infections:

1. Behavioral Factors: Certain behaviors, such as smoking and a history of multiple sexual partners, increase the risk of persistent HPV infections and cancer progression.
2. Oral Contraceptives: Long-term use of oral contraceptives has been linked to a higher risk of persistent HPV infections, particularly in women.
3. Pregnancy: Changes in the immune system during pregnancy may heighten susceptibility to HPV infections.
4. Male Circumcision: Research suggests that male circumcision may reduce the risk of HPV transmission and infection.
5. Coinfection with Other STIs: Concurrent infections with other sexually transmitted infections like herpes simplex virus (HSV) or Chlamydia can influence the course and persistence of HPV infections.
6. Nutritional Factors: Some studies indicate that specific nutritional deficiencies could affect the immune response to HPV, influencing infection outcomes.

Understanding the multifaceted nature of HPV infections involves considering various factors—viral, host-related, behavioral, and environmental. This comprehensive perspective is essential for developing holistic prevention and management strategies within public health initiatives.

Social and Economic Factors:

1. Socioeconomic Status: Individuals with lower socioeconomic status may encounter barriers to accessing preventive healthcare services, including HPV vaccination and regular screenings.
2. Education: Limited education and awareness about sexual health practices and preventive measures can contribute to higher rates of HPV infection.
3. Healthcare Disparities: Disparities in healthcare access and utilization can impact the likelihood of early detection and treatment of HPV infections, influencing health outcomes.





Figure 1: Pathophysiology of HPV

Limitations and Considerations:

- There is no single treatment that universally works for all cases.
- The effectiveness of treatment can vary depending on the type, location, and size of warts.
- Recurrence is often a challenge, particularly with persistent infections.
- Treatment decisions should take into account individual health factors, preferences, and potential side effects.

It's important to recognize that while treatments aim to manage symptoms and reduce the risk of complications, none guarantee complete eradication of the virus. Prevention through vaccination, safe sexual practices, and regular screenings remains critical for managing the overall impact of HPV on public health. Individualized treatment plans should be developed in consultation with healthcare professionals, based on a thorough assessment of each patient's specific condition and needs.

Treatment Approach for HPV: Exploring PEG and Pyrazomycin Combination
 Introduction: Human Papillomavirus (HPV) presents a significant health challenge, necessitating innovative treatment strategies to enhance outcomes. Current treatments, such as those involving PEG and ribavirin, have limitations, prompting the exploration of alternative approaches.



Considerations: Both ribavirin and pyrazomycin have primarily been studied and utilized for various viral infections, and their roles in managing HPV are not well-established. Treatment

decisions for HPV typically rely on established therapies such as topical agents, surgical interventions, and immunotherapies. Consulting with a healthcare provider is essential to determine the most suitable and evidence-based treatment options for HPV infections based on individual circumstances. It's important to emphasize that ongoing research may offer more insights into the potential efficacy of different antiviral medications in HPV management.

As of my last update in January 2022, specific evidence supporting the use of ribavirin and pyrazomycin in HPV treatment was limited, and new developments may have emerged since then. Always refer to the latest medical literature and seek advice from healthcare professionals for the most current information.




Figure 2. Structure of Pyrazomycin




Figure 3. Structure of Ribavirin

Rationale for PEG and Pyrazomycin Combination: Pyrazomycin, with its structural similarities to ribavirin, suggests potential effectiveness in treating HPV. Combining it with PEG is expected to enhance treatment outcomes while minimizing adverse effects.

Supporting Evidence: Literature underscores pyrazomycin's antiviral properties, supporting its consideration as a viable treatment for HPV. Studies discussing response rates and side effect profiles further validate the proposed combination.

Safety Considerations: Given the known side effects of ribavirin and pyrazomycin, this review emphasizes evaluating the overall safety profile of the proposed treatment. Balancing efficacy with safety is crucial for effective management of HPV.

CONCLUSION:

This review endeavors to enhance the comprehension of HPV across different facets, aiming to support well-informed decision-making in healthcare practices and public health policy. In conclusion, the investigation into a treatment approach combining PEG and Pyrazomycin represents a promising path for optimizing HPV management. While definitive outcomes are not asserted, the structural similarities and potential synergies between these compounds justify further exploration. This proposed strategy seeks to provide a potentially effective and safer alternative to existing treatments, opening new avenues for improved HPV care.

REFERENCE:

- [1]. Gerein V., Rastorguev E., Gerein J., et al. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. *Ann Otol Rhinol Laryngol* 2005;114(6):463-71.
- [2]. Purceli M.C.S.C., Jotz G.P., Miranda S.L., et al. The use of ribavirin in the treatment of recurrent respiratory papillomatosis (PRR). *Acta AWHO* 1996;15(1):33-6.
- [3]. Gubinelli E., Posteraro P., Cocuroccia B., et al. Epidermodysplasia verruciformis with multiple mucosal carcinomas treated with pegylated interferon alfa and acitretin. *J Dermatolog Treat.*
- [4]. The Brazilian journal of infectious diseases: an official publication of the Brazilian Society of Infectious Diseases • July 2007 DOI: 10.1590/S1413-86702007000300017 • Source: PubMed Citations 11 Reads 1
- [5]. Abdel-Hady E.-S., Martin-Hirsch P., Duggan-Keen M., Stern P.L., Moore J.V., Corbitt G., Kitchener H.C., Hampson I.N. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. *Cancer Res.* 2001; 61:192–196. [PubMed]
- [6]. Adachi A., Kiyono T., Hayashi Y., Ohashi M., Ishibashi M. Detection of human papillomavirus (HPV) type 47 DNA in malignant lesions from epidermodysplasia verruciformis by protocols for precise typing of related HPV DNAs. *J. clin. Microbiol.* 1996; 34:369–375. [PMC free article] [PubMed]
- [7]. Adam J.L., Briggs M.W., McCance D.J. A mutagenic analysis of the E5 protein of human papillomavirus type 16 reveals that E5 binding to the vacuolar H⁺-ATPase is not sufficient for biological activity, using mammalian and yeast expression systems. *Virology.* 2000; 272:315–325. [PubMed]
- [8]. Adami H.-O., Kuper H., Andersson S.-O., Bergström R., Dillner J. Prostate cancer risk and serologic evidence of human papilloma virus infection: A populationbased case–control study. *Cancer Epidemiol. Biomarkers Prev.* 2003; 12:872–875. [PubMed]
- [9]. Adams M., Borysiewicz L., Fiander A., Man S., Jasani B., Navabi H., Lipetz C., Evans A.S., Mason M. Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. *Vaccine.* 2001; 19:2549–2556. [PubMed]
- [10]. Geijersstam V., Eklund C., Wang Z., Sapp M., Schiller J.T., Dillner J., Dillner L. A survey of seroprevalence of human papillomavirus types 16, 18 and 33 among children. *Int. J. Cancer.* 1999; 80:489–493. [PubMed]